Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires Live12-19

Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) 0.4% lower and The Health Care Select Sector SPDR Fund (XLV) marginally higher.

Bio-Path Holdings (BPTH) shares were up past 487% after the company said results from its preclinical trials of BP1001-A showed "enhanced insulin sensitivity," confirming it as a "potential" treatment for obesity and metabolic diseases in type 2 diabetes patients.

Mesoblast (MESO) stock was over 44% higher after the company said the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers.

Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492517687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492517687","market":"nz","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Mixed Premarket Thursday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were mixed premarket Thursday, with the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.4% lower and The Health Care Select Sector SPDR Fund (XLV) marginally higher.</p><p>Bio-Path Holdings (BPTH) shares were up past 487% after the company said results from its preclinical trials of BP1001-A showed \"enhanced insulin sensitivity,\" confirming it as a \"potential\" treatment for obesity and metabolic diseases in type 2 diabetes patients.</p><p>Mesoblast (MESO) stock was over 44% higher after the company said the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers.</p><p>Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Mixed Premarket Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Mixed Premarket Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 22:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) 0.4% lower and The Health Care Select Sector SPDR Fund (XLV) marginally higher.Bio-Path Holdings (BPTH) ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBB","symbol_name":"生物科技指数ETF-iShares Nasdaq","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492517687","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492517687","pubTimestamp":1734617403,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF  0.4% lower and The Health Care Select Sector SPDR Fund  marginally higher.Bio-Path Holdings  shares were up past 487% after the company said results from its preclinical trials of BP1001-A showed \"enhanced insulin sensitivity,\" confirming it as a \"potential\" treatment for obesity and metabolic diseases in type 2 diabetes patients.Mesoblast  stock was over 44% higher after the company said the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers.Sangamo Therapeutics  shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBB":"生物科技指数ETF-iShares Nasdaq","BK4139":"生物科技","BK4556":"基因编辑","SGMO":"Sangamo Therapeutics Inc","BK4588":"碎股","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","MESO":"Mesoblast Limited","BPTH":"Bio-Path Holdings, Inc.","BK4585":"ETF&股票定投概念"},"translate_title":"行业更新：周四盘前医疗保健股涨跌互现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPTH":0.9,"IBB":0.9,"MESO":0.9,"SGMO":0.9,"XLV":0.9},"content_text":"Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) 0.4% lower and The Health Care Select Sector SPDR Fund (XLV) marginally higher.Bio-Path Holdings (BPTH) shares were up past 487% after the company said results from its preclinical trials of BP1001-A showed \"enhanced insulin sensitivity,\" confirming it as a \"potential\" treatment for obesity and metabolic diseases in type 2 diabetes patients.Mesoblast (MESO) stock was over 44% higher after the company said the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers.Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492517687"}